50 results about "SLCO1B1" patented technology

The invention provides a human SLCO1B1 and ApoE (apolipoprotein E) gene polymorphism detection kit, comprising a PCR (polymerase chain reaction) buffer solution, dNTP (deoxy-ribonucleoside triphosphate), MgCl2, four groups of specific primers, four groups of specific probes, an internal standard system, HotStart Taq enzyme and UNG (uracil-N-glycosylase) enzyme. The detection kit has the advantages of high specificity, high sensitivity, ease and quickness of operation, high throughput, safety, objectiveness of result interpretation, and the like.

This invention relates to a method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has altered susceptibility to statin-induced myopathy.

The present invention discloses primers, probes and a kit for detecting the polymorphisms of gene ApoE and gene SLCO1B1, wherein the primers and the probes comprise primers and probes for detecting the polymorphic loci of T388C and C526T of the gene ApoE, and primers and probes for detecting the polymorphic loci of A388G and T521C of the gene SLCO1B1. According to the present invention, the kit is suitable for the selection of a variety of clinical samples, and has significant advantages of high specificity, high sensitivity, short experimental period, simple operation, safety, no toxicity, low cost, and the like.

The invention discloses a kit used for SNP detection of personalized medicine related genes of statin lipid-lowering medicine and a detecting method thereof. The kit comprises two forward primers and a reverse primer for detecting a locus rs17238540 of an the HMGCR gene, two forward primers and a reverse primer for detecting a locus rs7412 of an the APOE gene, two forward primers and a reverse primer for detecting a locus rs429358 of an the APOE gene, and two forward primers and a reverse primer for detecting a locus rs4149056 of an the SLCO1B1 gene. The kit used for the SNP detection of the personalized medicine related genes of the statin lipid-lowering medicine can conduct high throughput detection on the four loci, and a result of genotyping can be visually distinguished through software so as to achieve the purposes of quantitatively controlling metering of the statin lipid-lowering medicine and minimizing side effects.

The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.

The invention provides a primer-probe composition for detecting human SLCO1B1 and ApoE genetic typing, a kit and a detecting method, the primer-probe composition comprises a specific primer, a specific probe and an internal reference agent for ApoE and SLCO1B1 genetic typing. According to the primer-probe composition, the kit and the detecting method, investigation of polymorphism of four types ofgenetic typing of SLCO1B1*1b(388G-521T), SLCO1B1*5(388A-521C), ApoE-E4(388C-526C) and ApoE-E2(388T-526T) in SLCO1B1 and ApoE genetic typing in a human body blood DNA sample is conducted synchronously, the advantages of high sensitivity, high specificity, low cost and high throughput, easy and convenient operation, and short experimental period are achieved, and the technical superiority of low cost of gene detecting is achieved.

The invention discloses a kit and a method for simultaneously and rapidly detecting SLCO1B1 and ApoE gene polymorphism, and belongs to the technical field of gene detection. The kit comprises a sampletreating reagent, a gene testing reagent, a positive reference substance and a negative reference substance, the sample treating reagent is used for rapidly treating a human whole blood sample, and the gene testing reagent is separately packaged in a premixed single portion manner and includes an SLCO1B1 gene testing reagent and an ApoE gene testing reagent. According to the kit, convenient, rapid and efficient detection is achieved based on guarantee of detection specificity and sensitivity, detection steps are decreased, production cost and detection cost are reduced when detection reactiontime is shortened, and clinical detection, analysis and application are facilitated.

The invention provides a noninvasive detection kit for detecting hyperlipemia susceptible genes. The kit comprises specific primers and DNA (deoxyribonucleic acid) sequencing primers for detecting 3 mononucleotide polymorphism site genotypes (EcoRI on APOB gene, C677T (rs1801133) on MTHFR gene, and T521C (rs4149032) on SLCO1B1 gene), a PCR (polymerase chain reaction) component, a PCR product purification component, a DNA sequencing reaction component and the like. The kit evaluates the hyperlipemia attack risk level by detecting the 3 mononucleotide polymorphism site genotypes closely related to hyperlipemia on the gene level, and instructs people to prevent the occurrence of diseases in advance. The sampling method is an oral mucosa cell sampling method which is painless and noninvasive and avoids cross infection. The kit has the advantage of accurate and reliable sequencing detection result, and does not need to buy expensive imported special instruments; and thus, the method is easy to popularize.

The invention discloses a method for detecting genes affecting the efficacy of lipid-lowering drugs by combining a TaqMan-MGB probe and a real-time fluorescence quantitative PCR technique. The polymorphism of the genes affecting the efficacy of the lipid-lowering drugs in samples to be detected is detected, six SNP loci can be detected simultaneously, used primers and the TaqMan-MGB probe have high specificity, the risk of false positive caused by PCR product contamination can be reduced, the operation is simple and the result is accurate and reliable. According to the method, functional meaningful mutations such as SLCO1B1 c.521T>C (rs4149056), SLCO1B1 c.388A>G(rs2302683), SLCO1B1 c.-910G>A(rs4149015), ApoE c.388T> C(rs429358), ApoE c.526C>T(rs7412) and NPC1L1 c.-18C>A(rs41279633) are detected to assist clinicians to select appropriate drugs and doses or avoid occurring of drug interactions, the best therapeutic effect for patients is achieved, and thus the purpose of real ''individualized medication'' is achieved.

Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins) are prescribed to lower serum cholesterol levels and reduce the risk of CVD. Despite the success of statins, many patients abandon treatment owing to neuromuscular adverse drug reactions (ADRs). Genome-wide association studies have identified the single-nucleotide polymorphism (SNP) rs4149056 in the SLCO1B1 gene as being associated with an increased risk for statin-induced ADRs.

By studying slow-channel syndrome transgenic mouse models, this invention determined that statins trigger ADRs in mice expressing the mutant allele of the rs137852808 SNP in the nicotinic acetylcholine receptor (nAChR) α-subunit gene CHRNA1. Mice expressing this allele show a remarkable contamination of end-plates with caveolin-1 and develop early signs of neuromuscular degeneration upon statin treatment. The invention demonstrates that genes coding for nAChR subunits may contain variants associated with statin-induced ADRs.

The invention discloses a specific primmer and a liquid phase chip for solute carrier organic anion transporter 1B1 (SLCO1B1) gene signal nucleotide polymorphism (SNP) detection. The liquid phase chip mainly comprises allele specific primer extension (ASPE) primer pairs, microspheres and amplifiers, wherein each ASPE primer consists of a tag sequence at a 5' end and specific primers at a 3' end aiming at an SNP locus; the specific primers comprise SEQ ID NO.11 and SEQ ID NO.12 aiming at T521C SNP locus, SEQ ID NO.13 and SEQ ID NO.14 aiming at T89595C SNP locus, SEQ ID NO.15 and SEQ ID NO.16 aiming at A388G SNP locus, SEQ ID NO.17 and SEQ ID NO.18 aiming at C463A SNP locus, and/or SEQ ID NO.19 and SEQ ID NO.20 aiming at A1929C SNP locus; and the tag sequence is selected from SEQ ID NO.1 to SEQ ID NO.10. The coincidence rate of the liquid phase chip provided by the invention and the detection result of a sequencing method reaches 100 percent. And the prepared liquid phase chip for the SLCO1B1 gene SNP detection has high signal-to-noise ratio.

The invention discloses a primer combination for guiding related gene detection of individualized medications of a risuvastatin drug. The primer combination is characterized by including specific primers and probes for an ABCG2(rs2231142) gene locus and an SLCO1B1(rs4149056) gene locus. The invention further discloses a kit containing the primer combination and an analytical method of the kit. According to the primer combination, the characteristics of easy operation, the economical efficiency, rapid detection, the high accuracy, the good specificity and easy result interpretation are achieved, the polymorphism of related genes of the individualized medications of the risuvastatin drug is rapidly and accurately measured to lower the adverse reaction of common medications of the rosuvastatin drug in clinic, the medical cost is lowered, and social resources are saved.

The invention discloses a kit for detecting human hyperlipidemia sensitive genes. The kit comprises an APOE primer group, an SLCO1B1-1 primer group, an SLCO1B1-2 primer group, a COQ2 primer group anda CYP3A5 primer group. The human hyperlipidemia drug sensitive genes APOE, SLCO1B1, COQ2 and CYP3A5 are taken as detection objects. Through a combination of the specific primers and combination of a nucleic acid mass spectrometry detection technology, a rapid, simple and accurate detection of variation conditions of the related genes is realized.

The invention discloses a primer, a method and a kit for detecting SLCO1B1 gene mutation related to CHD (Coronary Atherosclerotic Heart Disease). The primer comprises two pairs of amplification primers aiming at a fifth exon sequence and a sixth exon sequence and a pair of sequencing primers; by adopting a Sanger sequencing technology, gene mutation related to the CHD can be rapidly detected. A result of detection completed by utilizing the primer, the method and the kit, which are disclosed by the invention, is accurate, and an important reference significance in early diagnosis and individualized treatment of the CHD is obtained.

The invention discloses a SNP fluorescence in situ hybridization sequencing detection method for ABCB1 and SLCO1B1. The method comprises the following steps: DNA of a sample to be tested is extracted;single-stranded derivatization is performed using the DNA as a template; different fluorescently-labeled first sequencing probes and second sequencing probes are simultaneously added to be hybridizedwith the single-stranded derivative; and finally, the hybridization result is interpreted. The method has high precision and good stability, and is fast, safe and easy for automatic operation. By themethod, precise typing of single nucleotide polymorphism can be completed in the cycle of single-stranded derivatization and hybridization reaction, thereby understanding the genotype of the subjectand achieving prevention of diseases caused by risk factors and clinical guidance for individualized medication.

The invention discloses a detection kit of methotrexate metabolism markers, and a detection method and application of the detection kit. The kit is used for detecting the gene polymorphism of the methotrexate metabolism markers ABCB1 (C3435T), MTHFR (C677T) and SLCO1B1 (c.1865+4846T>C). According to the invention, multiple RPA amplification and optimized pyrosequencing technologies are combined to detect the methotrexate drug dosage and the gene polymorphism related to adverse reaction prediction, the kit can be used for simultaneously detecting ABCB1 (C3435T), MTHFR (C677T) and SLCO1B1 (c.1865+4846T>C) gene polymorphism methotrexate drugs, and suggestions from the gene perspective are provided for clinical personalized medication.

The invention discloses a primer combination used for guiding lovastatin drug individualized medication related gene detection. The primer combination includes specific primers for APOA5(rs662799), CETP(rs708272) and SLCO1B1(rs2291073) gene loci and Taqman probes. The invention further discloses a kit comprising the primer combination and an analysis method thereof. The primer combination has theadvantages of being easy to operate, economical, rapid in detection, high in accuracy, good in specificity and simple in result interpretation, rapid and accurate determination for the lovastatin drugindividualized medication related gene polymorphism is achieved, so that adverse reactions of clinical lovastatin drug common medication are reduced, the medical cost is lowered, and the social resources are saved.

The invention discloses a combination of primers for guiding detection of a pravastatin individualized drug use related genes, and is characterized in that the combination includes specific primers and probes for SLCO1B1 (rs4149015), HMGCR (rs17244841) and LDLR (rs1433099) gene loci. The invention also discloses a kit and a method. The kit has the advantages of simple operation, economy, fast detection, high accuracy, good specificity and simple result interpretation, and realizes rapid and accurate determination of polymorphisms of the pravastatin individualized drug use related genes, so asto reduce adverse reactions of common drug use of pravastatin in clinic, reduce medical cost and save social resources.

The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.

The invention relates to a primer and probe composition for detecting SLCO1B1 and APOE (apolipoprotein E) gene polymorphism and a kit and a method. The primer and probe composition for detecting SLCO1B1 and APOE gene polymorphism comprises a first primer and a first probe and a second primer and a second probe, wherein the first primer and the first probe are used for detecting an SLCO1B1 locus; the second primer and the second probe are used for detecting an APOE locus; nucleotide sequences of the first primer are shown in SEQ ID No.1-4; nucleotide sequences of the first probe are shown in SEQ ID No.9-10; nucleotide sequences of the second primer are shown in SEQ ID No.5-8; and nucleotide sequences of the second probe are shown in SEQ ID No.11-12. The primer and probe composition has theadvantages of being high in detection flux and simple and convenient to operate.

The invention discloses an extraction-free reagent kit for detecting gene polymorphism of human APOE and SLCO1B1. The reagent kit comprises main reaction liquor, ApoE primer and probe mixed liquor 1,ApoE primer and probe mixed liquor 2, SLCO1B1 primer and probe mixed liquor 1, SLCO1B1 primer and probe mixed liquor 2, positive quality control and feminine quality control, wherein the main reactionliquor comprises DNA polymerase, four kinds of deoxyribonucleotide, Mg2+, Tris buffer liquor and ultrapure BSA, and the DNA polymerase includes TTX enzymes and/or HS-D-Taq enzymes. The reagent kit can directly complete test on whole blood samples and swab samples through a unique amplification system, and a primer and probe sequence and system taking account of specificity and sensitivity, the detection is completed in four reaction system closed pipes, so that pollution can be avoided; and in addition, the feminine quality control and the positive quality control in the reagent kit can effectively monitor false positivity and validity of reagents and operations, and can effectively control pollution and monitor the whole experiment process.